Add‐on felbamate vs placebo
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
1 finding from 1 review
- no estimate extracted1 study · 83 participantsVery low
Findings
What do systematic reviews say?
15 questions · 15 findings · 13 reviews · Epilepsy
No studies found 2 · 13.3%GRADE not reported 0 · 0%Very low 1 · 6.7%Low 2 · 13.3%Moderate 6 · 40%High 4 · 26.7%
Any dose of lacosamide vs placebo
50% or greater reduction in seizure frequency · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide leads to higher 50% or greater reduction in seizure frequency compared with placebo (high certainty).
1 finding from 1 review
- RR 1.79 [1.55, 2.08]5 studies · 2199 participantsHigh
Add‐on lamotrigine vs placebo
50% or greater reduction in seizure frequency · people with drug‐resistant generalised tonic‐clonic seizures
Add‐on lamotrigine may leads to higher 50% or greater reduction in seizure frequency compared with placebo (low certainty).
1 finding from 1 review
- Lamotrigine add‐on therapy for drug‐resistant generalised tonic‐clonic seizures 2020 · Cochrane Headline outcomes onlyRR 1.88 [1.43, 2.45]2 studies · 270 participantsLow
Losigamone vs placebo
50% or greater reduction in seizure frequency · people with focal epilepsy
Losigamone probably leads to higher 50% or greater reduction in seizure frequency compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.76 [1.14, 2.72]2 studies · 467 participantsModerate
Sulthiame add‐on vs placebo
50% or greater reduction in seizure frequency · patients between 3 to 15 months of age with West syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Lamotrigine vs placebo
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Summary of findings: lamotrigine probably leads to higher 50% or greater reduction in seizure frequency (ITT analysis) compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.8 [1.45, 2.23]12 studies · 1322 participantsModerate
Rufinamide vs placebo
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher 50% or greater reduction in seizure frequency ‐ ITT analysis compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.79 [1.44, 2.22]6 studies · 1759 participantsModerate
Topiramate vs placebo
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Topiramate leads to higher 50% or greater reduction in seizure frequency (ITT analysis) compared with placebo (high certainty).
1 finding from 1 review
- RR 2.71 [2.05, 3.59]12 studies · 1650 participantsHigh
Brivaracetam vs placebo
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Brivaracetam probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.81 [1.53, 2.14]6 studies · 2411 participantsModerate
Carisbamate vs placebo
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Carisbamate probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.36 [1.14, 1.62]4 studies · 2211 participantsModerate
Flunarizine vs placebo
50% or greater reduction in seizure frequency Number of seizures · patients with drug‐resistant epilepsy
Flunarizine showed no clear difference in 50% or greater reduction in seizure frequency Number of seizures compared with placebo (high certainty).
1 finding from 1 review
- Calcium antagonists as an add‐on therapy for drug‐resistant epilepsy 2013 · Cochrane Headline outcomes onlyRR 1.53 [0.59, 3.96]1 study · 93 participantsHigh
Nimodipine vs placebo
50% or greater reduction in seizure frequency Number of seizures · patients with drug‐resistant epilepsy
Nimodipine showed no clear difference in 50% or greater reduction in seizure frequency Number of seizures compared with placebo (moderate certainty).
1 finding from 1 review
- Calcium antagonists as an add‐on therapy for drug‐resistant epilepsy 2013 · Cochrane Headline outcomes onlyRR 7.78 [0.46, 130.88]1 study · 17 participantsModerate
Tiagabine vs placebo control
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Tiagabine leads to higher 50% or greater reduction in seizure frequency (Intention‐to‐treat… compared with placebo control (high certainty).
1 finding from 1 review
- RR 3.16 [1.97, 5.07]3 studies · 769 participantsHigh
Osmotic‐release oral system methylphenidate vs placebo
50% or greater reduction in seizure frequency · people with ADHD and epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
- Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only
50% or greater reduction in seizure frequency · people with ADHD and epilepsy
Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of people achieving 50% or greater reduction in monthly… compared with risperidone and previous ASM only (low certainty).
1 finding from 1 review
- Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes onlyRR 2.79 [0.84, 9.24]1 study · 56 participantsLow